Example: Heart Attack

Clinical Trials on Carotid Body Tumor

Total 100 results

NCT04583384

Not yet recruiting

In Vivo Succinate Detection After External Beam Radiation Therapy in SDHx- Paragangliomas

Conditions: Paraganglioma of Head and Neck
NCT03946527

Not yet recruiting

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)

Conditions: Paraganglioma; Pheochromocytoma
NCT00911729

Terminated

Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma

Conditions: Pheochromocytoma; Paraganglioma
NCT04573816

Not yet recruiting

Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma

Conditions: Pheochromocytoma; Paraganglioma
NCT03344016

Recruiting

Multicenter Pheochromocytoma and Paraganglioma Evaluation

Conditions: Pheochromocytoma; Paraganglioma
NCT03839498

Recruiting

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Conditions: Pheochromocytoma; Paraganglioma
NCT01371201

Recruiting

First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma

Conditions: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
NCT00843037

Active, not recruiting

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma

Conditions: Paraganglioma; Pheochromocytoma
NCT02961491

Approved for marketing

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Conditions: Pheochromocytoma; Paraganglioma
NCT02186678

Unknown status

Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation

Conditions: Paragangliomas; Pheochromocytomas
NCT01967576

Active, not recruiting

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Conditions: Pheochromocytoma; Paraganglioma
NCT00874614

Active, not recruiting

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Conditions: Pheochromocytoma; Paraganglioma
NCT01941849

Withdrawn

Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma

Conditions: Phaeochromocytoma; Paraganglioma
NCT00458952

Completed

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Conditions: Pheochromocytoma; Paraganglioma
NCT03008369

Active, not recruiting

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Conditions: Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma
NCT04187404

Recruiting

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Conditions: Adrenocortical Carcinoma; Pheochromocytoma; Paraganglioma
NCT01163383

Available

131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma

Conditions: Neuroblastoma; Childhood Metastatic Pheochromocytoma; Paraganglioma
NCT01838187

Available

Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Conditions: Neuroblastoma; Pheochromocytoma; Paraganglioma
NCT00339131

Completed

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Conditions: Pheochromocytoma; Paraganglioma; Carcinoid
NCT04605848

Recruiting

Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT)

Conditions: Pheochromocytoma; Paraganglioma
NCT00188019

Completed

Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers

Conditions: Paraganglioma; Pheochromocytoma
NCT01340794

Terminated

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Conditions: Extra-Adrenal Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Paraganglioma; Recurrent Adrenal Gland Pheochromocytoma
NCT03206060

Recruiting

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Neuroendocrine Neoplasms
NCT02302833

Recruiting

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Conditions: Locally Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Regional Adrenal Gland Pheochromocytoma; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma
NCT03165721

Completed

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Conditions: Paraganglioma; Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Renal Neoplasms; Pheochromocytoma